IFNB1 and myeloid sarcoma: Regarding treated MS patients, clonal persistence was evaluated in 16 patients receiving natalizumab (n = 7), fingolimod (n = 5), interferon-beta (n = 3) or dimethyl fumarate (n = 1) within three different studies (Table 2).